Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 12/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.45 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.44 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3316360 | 0.83 | MAPK14 (0.52) | ADORA2AADORA1MAPK14MAPK13MAPK12 | |
| SCHEMBL3317626 | 0.73 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3815107 | 0.71 | MAPK14 (0.45) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1417024 | 0.69 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11HDAC1 | |
| SCHEMBL3314897 | 0.68 | ALDH1A1 (0.67) | HDAC1HDAC8HDAC6 | |
| SCHEMBL14510998 | 0.68 | MAPK14 (0.50) | MAPK14MAPK13MAPK12MAPK11HDAC1 | |
| SCHEMBL13939383 | 0.67 | MAPK14 (0.73) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4017599 | 0.67 | ADORA1 (0.76) | ADORA2AADORA1NR1H4HDAC1HDAC8 | |
| SCHEMBL2984112 | 0.66 | CAMKK2 (0.70) | CAMKK2 | |
| SCHEMBL12764358 | 0.66 | TAS1R3 (0.55) | MAPK14MAPK13MAPK12MAPK11NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652044-B2 | P-38 inhibitors | NOVARTIS A.G. (CH) | 2010-01-26 | — | — | US | claimed |
| US-20100004298-A1 | P-38 INHIBITORS | DONG QING | 2010-01-07 | — | — | US | claimed |
| EP-1635824-B1 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | NOVARTIS AG (CH) | 2009-08-19 | — | — | EP | claimed |
| EP-1635824-A2 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | Novartis AG (CH) | 2006-03-22 | — | — | EP | claimed |
| WO-2005000298-A2 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | NOVARTIS AG (CH) | 2005-01-06 | — | — | WO | claimed |
| US-20040254236-A1 | P-38 inhibitors | NOVARTIS AG (CH) | 2004-12-16 | — | — | US | claimed |
| US-7652044-B2 | P-38 inhibitors | NOVARTIS A.G. (CH) | 2010-01-26 | — | — | US | disclosed |
| US-7652044-B2 | P-38 inhibitors | NOVARTIS A.G. (CH) | 2010-01-26 | — | — | US | disclosed |
| US-20100004298-A1 | P-38 INHIBITORS | DONG QING | 2010-01-07 | — | — | US | disclosed |
| US-20100004298-A1 | P-38 INHIBITORS | DONG QING | 2010-01-07 | — | — | US | disclosed |
| EP-1635824-B1 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | NOVARTIS AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| EP-1635824-B1 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | NOVARTIS AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| US-20040254236-A1 | P-38 inhibitors | NOVARTIS AG (CH) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004298-A1 | P-38 INHIBITORS | MAPK8, MAPK1, MAP3K8 | ADORA2A 2748/4885ADORA1 3275/4885MAPK14 21/4885 |
| US-20040254236-A1 | P-38 inhibitors | MAPK8, MAP3K8, MAPK1 | ADORA2A 3015/4885ADORA1 3537/4885MAPK14 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.